Banner Life Sciences Receives Favorable Appellate Court Decision in Biogen Patent Infringement Dispute
We are pleased with the Federal Circuits decision, said Franck Rousseau, M.D., Chief Executive Officer of Banner.
- We are pleased with the Federal Circuits decision, said Franck Rousseau, M.D., Chief Executive Officer of Banner.
- BAFIERTAM (monomethyl fumarate) is an oral 95 mg delayed-release capsule indicated for the treatment of patients with relapsing forms of multiple sclerosis.
- While BAFIERTAM has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, the precise mechanism of action has not been fully elucidated.
- Banner Life Sciences LLC, a privately held clinical-stage pharmaceutical company, combines a proven history of formulation expertise with proprietary technologies to create specialty pharmaceuticals that solve real unmet clinical needs.